Literature DB >> 16864594

Hyaluronan stimulates transformation of androgen-independent prostate cancer.

Shi-Lung Lin1, Donald Chang, Shao-Yao Ying.   

Abstract

Interaction between extracellular matrices and cancer cell receptors frequently alters signal transduction pathways, leading to malignant transformation and metastasis. Hyaluronan (HA) is a tumor promoter and enhancer in transformation of androgen-independent (AI) prostate cancer (CaP); however, the signal transduction pathway involved in this mechanism remains unclear. We report here that HA-mediated CD168, a receptor for HA-mediated motility, and its downstream signal molecules, including ROK1, Gab-1, PI3K*p110alpha and eIF4E3, accelerate the progression of AI rather than androgen-dependent CaP and enhance AI cell invasion and metastasis in human bone marrow endothelial layers. MicroRNA-based small hairpin RNA-mediated suppression of ROK1 can reverse the malignant role of CD168 signaling in human AI CaP PC3 and DU145 cells. This differential activation of ROK-PI3K signaling in AI CaP cells may provide clues to shed light on some mechanisms of cancer relapse after androgen ablation. These findings reveal a novel signal transduction mechanism for matrix-mediated cancer transformation and metastasis in hormone-refractory CaP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864594     DOI: 10.1093/carcin/bgl134

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

1.  Loss of mir-146a function in hormone-refractory prostate cancer.

Authors:  Shi-Lung Lin; Angela Chiang; Donald Chang; Shao-Yao Ying
Journal:  RNA       Date:  2008-01-03       Impact factor: 4.942

Review 2.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

3.  Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

4.  SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Chunhua Liu; Xuefei Shi; Li Wang; Ying Wu; Feiyan Jin; Cuiqing Bai; Yong Song
Journal:  Tumour Biol       Date:  2014-03-15

5.  Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion.

Authors:  Katerina Kouvidi; Aikaterini Berdiaki; Dragana Nikitovic; Pavlos Katonis; Nikos Afratis; Vincent C Hascall; Nikos K Karamanos; George N Tzanakakis
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

6.  Upregulation of hyaluronan-mediated motility receptor in hepatocellular carcinoma predicts poor survival.

Authors:  Xiaohu He; Weijia Liao; Yulan Li; Yongqin Wang; Qian Chen; Junfei Jin; Songqing He
Journal:  Oncol Lett       Date:  2015-10-01       Impact factor: 2.967

7.  Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.

Authors:  Lei Wang; Jeffrey Ho; Carlotta Glackin; Manuela Martins-Green
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 8.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

9.  Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer.

Authors:  Dali Huang; George P Casale; Jun Tian; Subodh M Lele; Vladimir M Pisarev; Melanie A Simpson; George P Hemstreet
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

10.  3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro.

Authors:  Stephen J Florczyk; Gang Liu; Forrest M Kievit; Allison M Lewis; Jennifer D Wu; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2012-07-06       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.